Relationship between epidermal growth factor receptor gene mutation and copy number in Chinese patients with non-small cell lung cancer
- PMID: 22572014
- PMCID: PMC3777451
- DOI: 10.5732/cjc.011.10409
Relationship between epidermal growth factor receptor gene mutation and copy number in Chinese patients with non-small cell lung cancer
Abstract
Epidermal growth factor receptor (EGFR) gene mutation and copy number are useful predictive markers that guide the selection of non-small cell lung cancer (NSCLC) patients for EGFR-targeting therapy. This study aimed to investigate the correlation between EGFR gene mutation and copy number and clinicopathologic characteristics of Chinese patients with NSCLC. NSCLC specimens collected from 205 patients between November 2009 and January 2011 were selected to detect EGFR gene mutations with real-time polymerase chain reaction (RT-PCR) and to detect EGFR gene copy number with fluorescence in situ hybridization (FISH). EGFR mutations primarily occurred in females, non-smokers, and patients with adenocarinomas (all P < 0.001). Tissues from 128 (62%) patients were FISH-positive for EGFR, including 37 (18%) with gene amplification and 91 (44%) with high polysomy. EGFR gene mutation was correlated with FISH-positive status (R = 0.340, P < 0.001). Multivariate analysis showed that not smoking (OR = 5.910, 95% CI = 2.363-14.779, P < 0.001) and having adenocarcinoma (OR = 0.122, 95% CI = 0.026-0.581, P = 0.008) were favorable factors for EGFR gene mutation. These results show a high frequency of EGFR FISH positivity in NSCLC tissues from Chinese patients and a significant relevance between EGFR gene mutations and FISH-positive status. Among the FISH-positive samples, EGFR gene mutation occurred more frequently in samples with gene amplification compared to those with high polysomy, suggesting that EGFR mutation and gene amplification should be used as clinical decision parameters to predict response to EGFR-targeting therapy.
Figures


Similar articles
-
Association between epidermal growth factor receptor gene copy number and ERCC1, BRCA1 protein expression in Chinese patients with non-small cell lung cancer.Med Oncol. 2014 Mar;31(3):803. doi: 10.1007/s12032-013-0803-5. Epub 2014 Jan 23. Med Oncol. 2014. PMID: 24452282
-
Clinicopathologic features and prognostic implications of epidermal growth factor receptor (EGFR) gene copy number and protein expression in non-small cell lung cancer.Lung Cancer. 2006 Dec;54(3):387-98. doi: 10.1016/j.lungcan.2006.08.015. Epub 2006 Sep 29. Lung Cancer. 2006. PMID: 17011067
-
[Correlation between EGFR gene mutation and high copy number and their association with the clinicopathological features in Chinese patients with non-small cell lung cancer].Zhonghua Zhong Liu Za Zhi. 2011 Sep;33(9):666-70. Zhonghua Zhong Liu Za Zhi. 2011. PMID: 22340046 Chinese.
-
East meets West: ethnic differences in epidemiology and clinical behaviors of lung cancer between East Asians and Caucasians.Chin J Cancer. 2011 May;30(5):287-92. doi: 10.5732/cjc.011.10106. Chin J Cancer. 2011. PMID: 21527061 Free PMC article. Review.
-
EGFR mutation frequency in Middle East and African non-small cell lung cancer patients: a systematic review and meta-analysis.BMC Cancer. 2018 Sep 14;18(1):891. doi: 10.1186/s12885-018-4774-y. BMC Cancer. 2018. PMID: 30217176 Free PMC article.
Cited by
-
Echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase rearrangement and epidermal growth factor receptor mutation coexisting in Chinese patients with lung adenocarcinoma.Thorac Cancer. 2014 Sep;5(5):411-6. doi: 10.1111/1759-7714.12111. Epub 2014 Aug 25. Thorac Cancer. 2014. PMID: 26767032 Free PMC article.
-
Assessment of epidermal growth factor receptor mutation/copy number and K-ras mutation in esophageal cancer.J Thorac Dis. 2016 Jul;8(7):1753-63. doi: 10.21037/jtd.2016.06.17. J Thorac Dis. 2016. PMID: 27499966 Free PMC article.
-
Mutation abundance affects the efficacy of EGFR tyrosine kinase inhibitor readministration in non-small-cell lung cancer with acquired resistance.Med Oncol. 2014 Jan;31(1):810. doi: 10.1007/s12032-013-0810-6. Epub 2013 Dec 14. Med Oncol. 2014. PMID: 24338271
-
Correlative analysis of gene mutation and clinical features in patients with non-small cell lung cancer.Transl Cancer Res. 2019 Jun;8(3):736-751. doi: 10.21037/tcr.2019.04.10. Transl Cancer Res. 2019. PMID: 35116812 Free PMC article.
-
Clinical efficacy and safety of afatinib in the treatment of non-small-cell lung cancer in Chinese patients.Onco Targets Ther. 2018 Jan 24;11:529-538. doi: 10.2147/OTT.S136579. eCollection 2018. Onco Targets Ther. 2018. PMID: 29416353 Free PMC article. Review.
References
-
- Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90. - PubMed
-
- Dahabreh IJ, Linardou H, Siannis F, et al. Somatic EGFR mutation and gene copy gain as predictive biomarkers for response to tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res. 2010;16:291–303. - PubMed
-
- Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (the IDEAL 1 Trial) J Clin Oncol. 2003;21:2237–2246. - PubMed
-
- Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA. 2003;290:2149–2158. - PubMed
-
- Miller VA, Kris MG, Shah N, et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol. 2004;22:1103–1109. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous